Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
177Lu-PSMA-617 launch preparations are progressing,
ready to meet immediate launch demand upon approval in US
Prognosis remains poor for
patients with mCRPC
Most diagnosed
cancer in men¹
2nd
>80%
Of patients
metastatic at the time
of CRPC diagnosis²
~10
Months median OS
on available
treatment options³
Building foundation for strong launch upon approval in US
■ 177 Lu-PSMA-617 uniquely positioned to address unmet needs in
mCRPC with strong data on OS (median OS 15.3 months) and rPFS
Disease state education campaign on PSMA as an important
phenotypic biomarker
■ Growth in PSMA awareness from 31% to 66% over last 12 months4
Focused on activating >200 top treatment centers at launch for PSMA
■ Expecting gradual ramp-up due to diagnostic, process set-up, licensure
FDA BTD granted in June 2021
■
Filing to FDA on track for H2 2021
See slide 55 for references.
29 Investor Relations | Q2 2021 Results
1 NOVARTIS | Reimagining MedicineView entire presentation